Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

  • Technology appraisal guidance
  • TA562
  • Published: 

History

Documents created during the development process.

Declaration of interests

Expected publication

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators